Authors
Latest:
Dr. Philip on Adverse Events With Lutathera in NETsPhilip A. Philip, MD, PhD, FRCP, professor of medicine, Wayne State University School of Medicine, clinical professor of oncology at Barbara Ann Karmanos Cancer Institute, discusses adverse events (AEs) associated with Lutathera (lutetium Lu 177 dotatate) in neuroendocrine tumors (NETs).
Latest:
Dr. Paty on High-Risk Period for Rectal Tumor RegrowthPhilip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.
Latest:
Dr. Bierman on Unmet Needs for Patients With CNS Involvement in Aggressive NHLPhilip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).
Latest:
Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLCPhilip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.
Latest:
Drug Interactions With Tyrosine Kinase InhibitorsTyrosine Kinase Inhibitors (TKIs) are indicated for the treatment of a variety of malignancies, due to their ability to interfere with cell communication and growth. This review focuses on interactions that affect TKI metabolism.
Latest:
Combination BRAF-MEK Inhibition With Dabrafenib and Trametinib for BRAF-Mutant MelanomaIt is estimated that in 2014 more than 76,000 people will be diagnosed with melanoma and approximately 9700 people will die from the malignancy.
Latest:
Dr. Buffington on MRI Fusion for Prostate CancerPhilip J. Buffington, MD, chief medical officer, The Urology Group, discusses MRI fusion-guided biopsy in patients with prostate cancer.
Latest:
Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBCA review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.
Latest:
Dr. Philip McCarthy on Lenalidomide Maintenance for Multiple MyelomaPhilip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.
Latest:
Dr McCarthy on Neutrophil Activity in Multiple MyelomaPhilip McCarthy, MD, discusses a study of neutrophil gene signatures within focal lesions that are linked to progression-free survival in multiple myeloma.
Latest:
Dr. Philip on Evofosfamide for Pancreatic CancerPhilip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses the use of the investigational drug evofosfamide for pancreatic cancer.
Latest:
Dr. Poortmans on Impact of Multidisciplinary Approach on Side Effect ManagementPhilip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.
Latest:
Dr. Kantoff on Future Research Efforts in Prostate CancerPhilip W. Kantoff, MD, discusses future research efforts in prostate cancer.
Latest:
Dr. Moreau on the FDA Approval of Isatuximab Plus Carfilzomib/Dexamethasone in Multiple MyelomaPhilippe Moreau, MD, discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
Latest:
Dr. Philippe Ruszniewski on NETTER-1 Study ResultsPhilippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase 3 NETTER-1 study.
Latest:
Dr Koo on the Clinical Utility of PSMA PET in Prostate CancerPhillip J. Koo, MD, discusses the clinical use of PSMA PET imaging in patients with prostate cancer.
Latest:
Nonmetastatic CRPC: Treatment SelectionAn in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.
Latest:
Dr. Moreau on the CASSIOPEIA Trial in Transplant-Eligible MyelomaPhillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.
Latest:
Autologous Stem Cell Transplantation in Multiple MyelomaPhyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses the outcomes of a study investigating autologous stem cell transplantation (ASCT) in elderly patients with multiple myeloma.
Latest:
Highlights from Two Key Symposiums: Reporting on new research and emerging trends in breast and liver cancer.Reporting on new research and emerging trends in breast and liver cancer.
Latest:
Dr. Filosso on Future of Treating Patients With Lung NETsPier Luigi Filosso, MD, associate professor of Thoracic Surgery, University of Torino, Italy, discusses future approaches to treating patients with neuroendocrine tumors of lung origin.
